Canopy Growth
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. The last earnings update was 8 days ago. More info.
Add to Portfolio Compare Print
- Canopy Growth has significant price volatility in the past 3 months.
WEED Share Price and Events
7 Day Returns
1 Year Returns
WEED Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Canopy Growth (WEED) | -5.4% | 2.2% | 33.9% | 113% | 1948.6% | - |
| CA Pharmaceuticals | -0.6% | 9.5% | 19.7% | -8.1% | 887.4% | -30.3% |
| CA Market | 2.2% | 4.5% | 5.4% | 0.5% | 24% | 6.1% |
1 Year Return vs Industry and Market
- WEED outperformed the Pharmaceuticals industry which returned -8.1% over the past year.
- WEED outperformed the Market in Canada which returned 0.5% over the past year.
Price Volatility
Related Companies
WEED Value
Is Canopy Growth undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Canopy Growth. This is due to cash flow or dividend data being unavailable. The share price is CA$59.41.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Canopy Growth's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Canopy Growth's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in CAD | CA$-1.79 |
| TSX:WEED Share Price ** | TSX (2019-02-21) in CAD | CA$59.41 |
| Canada Pharmaceuticals Industry PE Ratio | Median Figure of 15 Publicly-Listed Pharmaceuticals Companies | 21.51x |
| Canada Market PE Ratio | Median Figure of 552 Publicly-Listed Companies | 14.82x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Canopy Growth.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = TSX:WEED Share Price ÷ EPS (both in CAD) = 59.41 ÷ -1.79 |
-33.27x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Canopy Growth is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
- Canopy Growth is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does
Canopy Growth's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -33.27x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts |
96.9%per year |
| Canada Pharmaceuticals Industry PEG Ratio | Median Figure of 10 Publicly-Listed Pharmaceuticals Companies | 0.9x |
| Canada Market PEG Ratio | Median Figure of 257 Publicly-Listed Companies | 0.94x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Canopy Growth, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Canopy Growth's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in CAD | CA$21.07 |
| TSX:WEED Share Price * | TSX (2019-02-21) in CAD | CA$59.41 |
| Canada Pharmaceuticals Industry PB Ratio | Median Figure of 120 Publicly-Listed Pharmaceuticals Companies | 3.25x |
| Canada Market PB Ratio | Median Figure of 2,330 Publicly-Listed Companies | 1.55x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = TSX:WEED Share Price ÷ Book Value per Share (both in CAD) = 59.41 ÷ 21.07 |
2.82x |
* Primary Listing of Canopy Growth.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Canopy Growth is good value based on assets compared to the CA Pharmaceuticals industry average.
Value checks
We assess Canopy Growth's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Canopy Growth has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
WEED Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Canopy Growth's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
- Canopy Growth's earnings growth is expected to exceed the Canada market average.
- Canopy Growth's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| TSX:WEED Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts | 96.9% |
| TSX:WEED Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 11 Analysts | 47.4% |
| Canada Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 85.8% |
| Canada Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 49.2% |
| Canada Market Earnings Growth Rate | Market Cap Weighted Average | 18% |
| Canada Market Revenue Growth Rate | Market Cap Weighted Average | 6.9% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 11 Analyst Estimates (S&P Global) | See Below |
| Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-03-31 | 2,408 | 1 | ||
| 2022-03-31 | 1,743 | 2 | ||
| 2021-03-31 | 1,343 | 189 | 7 | |
| 2020-03-31 | 813 | -142 | 10 | |
| 2019-03-31 | 242 | -415 | -427 | 11 |
| Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 155 | -332 | -411 |
| 2018-09-30 | 94 | -257 | -477 |
| 2018-06-30 | 88 | -137 | -142 |
| 2018-03-31 | 78 | -82 | -70 |
| 2017-12-31 | 70 | -60 | -21 |
| 2017-09-30 | 58 | -41 | -19 |
| 2017-06-30 | 49 | -36 | -13 |
| 2017-03-31 | 40 | -27 | -8 |
| 2016-12-31 | 30 | -14 | -1 |
| 2016-09-30 | 24 | -16 | -7 |
| 2016-06-30 | 18 | -14 | -8 |
| 2016-03-31 | 13 | -14 | -3 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 11 Analyst Estimates (S&P Global) | See Below |
All data from Canopy Growth Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CAD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-03-31 | ||||
| 2022-03-31 | ||||
| 2021-03-31 | 0.33 | 0.35 | 0.31 | 2.00 |
| 2020-03-31 | -0.43 | -0.29 | -0.60 | 4.00 |
| 2019-03-31 | -1.65 | -0.71 | -2.36 | 4.00 |
| Date (Data in CAD Millions) | EPS * |
|---|---|
| 2018-12-31 | -1.79 |
| 2018-09-30 | -2.39 |
| 2018-06-30 | -0.76 |
| 2018-03-31 | -0.40 |
| 2017-12-31 | -0.13 |
| 2017-09-30 | -0.13 |
| 2017-06-30 | -0.09 |
| 2017-03-31 | -0.06 |
| 2016-12-31 | -0.01 |
| 2016-09-30 | -0.07 |
| 2016-06-30 | -0.09 |
| 2016-03-31 | -0.05 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Canopy Growth's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Canopy Growth has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
WEED Past Performance
How has Canopy Growth performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Canopy Growth does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Canopy Growth's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Canopy Growth's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
All data from Canopy Growth Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CAD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 155.10 | -411.38 | 445.62 | 8.50 |
| 2018-09-30 | 93.75 | -477.37 | 329.07 | 3.53 |
| 2018-06-30 | 87.99 | -141.58 | 180.24 | 2.08 |
| 2018-03-31 | 77.95 | -70.35 | 131.13 | 1.45 |
| 2017-12-31 | 69.80 | -20.80 | 94.76 | 0.38 |
| 2017-09-30 | 57.86 | -19.39 | 65.74 | 0.53 |
| 2017-06-30 | 48.78 | -12.63 | 50.47 | 0.54 |
| 2017-03-31 | 39.90 | -7.52 | 38.55 | 0.81 |
| 2016-12-31 | 30.28 | -0.65 | 29.47 | 1.63 |
| 2016-09-30 | 24.01 | -6.96 | 24.65 | 1.38 |
| 2016-06-30 | 17.97 | -8.46 | 20.53 | 1.09 |
| 2016-03-31 | 12.70 | -3.50 | 17.33 | 0.72 |
| 2015-12-31 | 8.41 | 0.32 | 12.83 | 0.49 |
| 2015-09-30 | 5.57 | 1.00 | 11.00 | 0.34 |
| 2015-06-30 | 3.42 | -5.30 | 9.72 | 0.19 |
| 2015-03-31 | 1.90 | -7.48 | 8.10 | 0.21 |
| 2014-12-31 | 1.15 | -8.93 | 6.99 | 0.16 |
| 2014-09-30 | 0.50 | -7.07 | 5.32 | 0.12 |
| 2013-12-31 | -0.93 | 0.93 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Canopy Growth has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Canopy Growth has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Canopy Growth improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Canopy Growth's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Canopy Growth has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
WEED Health
How is Canopy Growth's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Canopy Growth's finances.
The net worth of a company is the difference between its assets and liabilities.
- Canopy Growth is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Canopy Growth's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 6.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Canopy Growth Company Filings, last reported 1 month ago.
| Date (Data in CAD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 7,423.68 | 791.50 | 4,933.50 |
| 2018-09-30 | 1,840.82 | 910.16 | 448.16 |
| 2018-06-30 | 1,224.46 | 620.29 | 657.90 |
| 2018-03-31 | 1,243.24 | 8.42 | 322.56 |
| 2017-12-31 | 1,019.86 | 8.79 | 237.71 |
| 2017-09-30 | 731.57 | 9.58 | 108.21 |
| 2017-06-30 | 682.86 | 9.91 | 115.49 |
| 2017-03-31 | 639.73 | 10.33 | 101.80 |
| 2016-12-31 | 251.52 | 7.17 | 92.50 |
| 2016-09-30 | 171.62 | 7.44 | 45.38 |
| 2016-06-30 | 132.38 | 4.13 | 19.53 |
| 2016-03-31 | 123.79 | 4.02 | 15.40 |
| 2015-12-31 | 132.05 | 3.97 | 19.72 |
| 2015-09-30 | 112.27 | 5.90 | 7.73 |
| 2015-06-30 | 42.92 | 1.89 | 15.17 |
| 2015-03-31 | 41.41 | 1.92 | 21.45 |
| 2014-12-31 | 21.67 | 1.88 | 5.77 |
| 2014-09-30 | 23.18 | 0.00 | 8.36 |
| 2013-12-31 | 3.83 | 0.04 | 2.09 |
- Canopy Growth's level of debt (10.7%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (1% vs 10.7% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Canopy Growth has sufficient cash runway for more than 3 years based on current free cash flow.
- Canopy Growth has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 115.4% each year.
Financial health checks
We assess Canopy Growth's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Canopy Growth has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
WEED Dividends
What is Canopy Growth's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
CA$2,000 of
Canopy Growth
shares you are expected to receive
CA$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Canopy Growth's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Canopy Growth's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 11 Analyst Estimates (S&P Global) | See Below |
| North America Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 2.7% |
| Canada Market Average Dividend Yield | Market Cap Weighted Average of 331 Stocks | 3.5% |
| Canada Minimum Threshold Dividend Yield | 10th Percentile | 1.1% |
| Canada Bottom 25% Dividend Yield | 25th Percentile | 2.1% |
| Canada Top 25% Dividend Yield | 75th Percentile | 5.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in CA$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-03-31 | ||
| 2022-03-31 | ||
| 2021-03-31 | ||
| 2020-03-31 | ||
| 2019-03-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Canopy Growth has not reported any payouts.
- Unable to verify if Canopy Growth's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Canopy Growth's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Canopy Growth afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Canopy Growth has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
WEED Management
CEO
| COMPENSATION | CA$2,516,014 |
| AGE | 51 |
| TENURE AS CEO | 0.7 years |
CEO Bio
Mr. Bruce A. Linton, BPA serves as Chief Executive Officer and Chairman at Canopy Rivers Inc. and serves its Director since April 2017 and served as Acting Chief Executive Officer. Mr. Linton is a Co-Founder of Canopy Growth Corporation (formerly Tweed Marijuana Inc) and has been its Co-Chief Executive Officer since August 28, 2014. Mr. Linton serves as the Chief Executive Officer and President for Clearford's two divisions: the Wastewater Systems Division and the Brooklin Concrete Division. He also served as the Chief Executive Officer and President at Martello Technologies, Inc. He has been Vice President of SC Stormont Inc., since January 2005. He served as Interim Chief Executive Officer of Canopy Growth Corporation (formerly Tweed Marijuana Inc). from August 2014 to February 2015. He served as the Chief Executive Officer of Clearford Industries Inc. (now known as Clearford Water Systems Inc.) from February 28, 2005 to December 31, 2012 and served as its President from February 28, 2005 to May 28, 2012. He served as Chief Executive Officer and President of Brooklin Concrete Products Limited. He served as the Chief Executive Officer of IWSSI. He served as the President of Clearford Industries from August 2009 to May 28, 2012. He was Re-Founder of Computerland.ca., and served as its General Manager from April 2002 to December 2004. He Co-founded webHancer Corp. in 1999 and served as its President and Chief Executive Officer. He has more than 10 years of senior executive experience in technology based companies, including Crosskeys Systems Corp. He has significant and recent experience with the introduction of both CrossKeys and Clearford to the Asia Pacific region. He has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He lead CrossKeys and Clearford's entry into the China market and in 2009 Clearford was awarded by the Canada-China Business Council for their market entry strategy. He was part of the leadership team for the Nasdaq/TSX IPO at CrossKeys Systems Corporation. He served as a Director of Asia Pacific Operations, Director of Business Relations and Director of Finance and Administration of CrossKeys. He serves as the Chairman of Canopy Growth Corporation (formerly Tweed Marijuana Inc) and Co-Chairman of Martello Technologies Group Inc. since August 15, 2018 and serves as its Director since April 29, 2013. He serves as a Director of and Bedrocan Cannabis Corp. He has been a Non-Executive Director of TW Holdings Limited since June 1, 2016. He serves as a Director of Carleton University and is Treasurer and Director at the non-profit youth organization Canadian World Youth. He served as a Director of Thermal Energy International Inc. since October 25, 2012 until November 28, 2016. He served as a Director of Clearford Industries Inc. from August 22, 2006 to October 16, 2013. He served as Director of Marchwell Ventures Ltd. from September 12, 2000 to November 17, 2011. He served as Director of Brooklin Concrete Products Limited. He was an industry liaison for Newbridge in 1992. He sits as Canada's representative on the World Bank's Water Sanitation Program Advisory Council as well as sitting on the Cleantech Advisory Board for Foreign Affairs Canada. He was Chairman of the Ottawa Community Loan Foundation, Board of Governor for Carleton University. He served as the President of the Nepean Skating Club and past-President of the Carleton University Students Association. He holds Bachelors of Public Administration from Carleton University (1986-1992).
CEO Compensation
- Bruce's compensation has increased whilst company is loss making.
- Bruce's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure
Average tenure of the Canopy Growth management team in years:
- The average tenure for the Canopy Growth management team is less than 2 years, this suggests a new team.
Management Team
Bruce Linton
Co-Founder
CA$3M
51
0.7 yrs
Mark Anthony Zekulin
President & Co-CEO
CA$2M
0.7 yrs
Timothy Saunders
Executive VP & CFO
CA$2M
3.7 yrs
Rade Kovacevic
Executive Vice President
CA$2M
1.3 yrs
Ann Gordon
Vice President of Corporate Finance
Peter Popplewell
Chief Technology Officer
1.1 yrs
Ru Wadasinghe
Chief Information Officer
Tom Shipley
Senior VP of Global Quality Assurance & Chief Science Officer
phil Shaer
Chief Legal Officer & VP of Human Resources
Jordan Sinclair
Director of Communications
Board of Directors Tenure
Average tenure and age of the Canopy Growth board of directors in years:
- The average tenure for the Canopy Growth board of directors is less than 3 years, this suggests a new board.
Board of Directors
Marc Wayne
Founding President & Director of Canopy Health Innovations
CA$331K
52
2.2 yrs
Peter Stringham
Director
CA$161K
68
2.4 yrs
Bruce Linton
Co-Founder
CA$3M
51
John Bell
Lead Director
CA$271K
71
Bill Newlands
Director
59
0.3 yrs
David Klein
Director
54
0.3 yrs
Judy Schmeling
Director
58
0.3 yrs
Robert Hanson
Director
55
0.3 yrs
Who owns this company?
Recent Insider Trading
- More shares have been bought than sold by Canopy Growth insiders in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (CA$) | Value (CA$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 13. Dec 18 | Buy | David Bigioni | Individual | 12. Dec 18 | 12. Dec 18 | 252 | CA$42.82 | CA$10,791 | ||
| 11. Dec 18 | Buy | David Bigioni | Individual | 10. Dec 18 | 10. Dec 18 | 3,600 | CA$41.99 | CA$151,164 | ||
| 11. Dec 18 | Sell | Robert Hanson | Individual | 06. Dec 18 | 06. Dec 18 | -5 | CA$29.85 | CA$-149 | ||
| 03. Oct 18 | Sell | Murray Goldman | Individual | 28. Sep 18 | 28. Sep 18 | -70,000 | CA$64.28 | CA$-4,499,600 | ||
| 03. Oct 18 | Sell | Mark Anthony Zekulin | Individual | 27. Sep 18 | 27. Sep 18 | -358,334 | CA$64.70 | CA$-23,182,562 | ||
| 02. Oct 18 | Sell | Murray Goldman | Individual | 28. Sep 18 | 28. Sep 18 | -300,000 | CA$65.74 | CA$-19,532,431 | ||
| 02. Oct 18 | Sell | HBAM Holdings Inc | Company | 27. Sep 18 | 27. Sep 18 | -307,845 | CA$64.66 | CA$-19,900,788 | ||
| 02. Oct 18 | Sell | Onbelay Capital Inc. | Company | 27. Sep 18 | 27. Sep 18 | -48,683 | CA$64.07 | CA$-3,119,120 | ||
| 02. Oct 18 | Sell | John Bell | Individual | 27. Sep 18 | 27. Sep 18 | -36,350 | CA$64.43 | CA$-2,342,030 | ||
| 29. Sep 18 | Sell | Christopher Schnarr | Individual | 27. Sep 18 | 27. Sep 18 | -107,868 | CA$65.44 | CA$-7,058,882 | ||
| 04. Jul 18 | Sell | Murray Goldman | Individual | 29. Jun 18 | 29. Jun 18 | -100,000 | CA$38.63 | CA$-3,823,062 | ||
Management checks
We assess Canopy Growth's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Canopy Growth has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
WEED News
Simply Wall St News
What Kind Of Shareholders Own Canopy Growth Corporation (TSE:WEED)?
Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Companies of this size are usually well known to retail investors, too.
Simply Wall St - – Full articleWhat You Must Know About Canopy Growth Corporation's (TSE:WEED) Financial Health
Mid-caps stocks, like Canopy Growth Corporation (TSE:WEED) with a market capitalization of CA$8.32b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. … Today we will look at WEED’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Check out our latest analysis for Canopy Growth
Simply Wall St - – Full articleCanopy Growth Corporation's (TSE:WEED) Path To Profitability
I’ve put together a brief outline of industry analyst expectations for WEED, its year of breakeven and its implied growth rate. … View our latest analysis for Canopy Growth According to the industry analysts covering WEED, breakeven is near. … How fast will WEED have to grow each year in order to reach the breakeven point by 2020?
Simply Wall St - – Full articleDoes Canopy Growth Corporation's (TSE:WEED) Debt Level Pose A Problem?
See our latest analysis for Canopy Growth Does WEED generate an acceptable amount of cash through operations? … With this growth in debt, WEED's cash and short-term investments stands at CA$101.80M , ready to deploy into the business. … I suggest you continue to research Canopy Growth to get a more holistic view of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for WEED’s future growth?
Simply Wall St - – Full articleWhat Does Canopy Growth Corporation's (TSE:WEED) Share Price Indicate?
I find that Canopy Growth’s ratio of 8.2x is trading slightly above its industry peers’ ratio of 6.96x, which means if you buy Canopy Growth today, you’d be paying a relatively reasonable price for it. … And if you believe that Canopy Growth should be trading at this level in the long run, there’s only an insignificant downside when the price falls to its real value. … Given that Canopy Growth’s share is fairly volatile (i.e.
Simply Wall St - – Full articleTop TSX Growth Stocks To Buy
Investors seeking to increase their exposure to growth should consider companies such as Canopy Growth and Sangoma Technologies. … TSX:WEED Future Profit Jan 2nd 18 Sangoma Technologies Corporation (TSXV:STC) Sangoma Technologies Corporation develops, manufactures, distributes, and supports voice and data connectivity components for software-based communication applications worldwide. … TSXV:ICC Future Profit Jan 2nd 18 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
Simply Wall St - – Full articleBest Growth Stocks To Buy Now
Individual investors like stocks with a high growth potential. … TOS is expected to deliver an extremely high earnings growth over the next couple of years of 56.41%, bolstered by a significant revenue which is expected to more than double. … TSX:TOS Future Profit Nov 22nd 17 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
Simply Wall St - – Full articleIs Canopy Growth Corporation (TSX:WEED) As Financially Strong As Its Balance Sheet Indicates?
Check out our latest analysis for Canopy Growth Is WEED’s level of debt at an acceptable level? … To assess this, I compare WEED's cash and other liquid assets against its upcoming debt. … Our analysis shows that WEED does have enough liquid assets on hand to meet its upcoming liabilities, which lowers our concerns should adverse events arise.
Simply Wall St - – Full articleWEED Company Info
Map
Description
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Details
| Name: | Canopy Growth Corporation |
| WEED | |
| Exchange: | TSX |
| Founded: | |
| CA$20,379,253,497 | |
| 343,027,327 | |
| Website: | http://www.canopygrowth.com |
| Address: |
Canopy Growth Corporation 1 Hershey Drive, Smiths Falls, Ontario, K7A 0A8, Canada |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| TSX | WEED | Common Shares | The Toronto Stock Exchange | CA | CAD | 27. Mar 2014 | |
| NYSE | CGC | Common Shares | New York Stock Exchange | US | USD | 27. Mar 2014 | |
| DB | 11L1 | Common Shares | Deutsche Boerse AG | DE | EUR | 27. Mar 2014 | |
| LSE | 0UO9 | Common Shares | London Stock Exchange | GB | CAD | 27. Mar 2014 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/02/22 00:35 |
| End of day share price update: | 2019/02/21 00:00 |
| Last estimates confirmation: | 2019/02/21 |
| Last earnings filing: | 2019/02/14 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/03/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
